IndexIQ Advisors LLC Invests $2.58 Million in Intersect ENT, Inc. (NASDAQ:XENT)

IndexIQ Advisors LLC bought a new position in Intersect ENT, Inc. (NASDAQ:XENT) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 94,707 shares of the medical equipment provider’s stock, valued at approximately $2,576,000. IndexIQ Advisors LLC owned approximately 0.28% of Intersect ENT at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Moors & Cabot Inc. acquired a new position in Intersect ENT during the 3rd quarter worth $269,000. Lumature Wealth Partners LLC bought a new stake in shares of Intersect ENT in the 3rd quarter valued at $106,000. Sphinx Trading LP bought a new stake in shares of Intersect ENT in the 3rd quarter valued at $190,000. Royal Bank of Canada increased its position in shares of Intersect ENT by 6.8% in the 2nd quarter. Royal Bank of Canada now owns 8,780 shares of the medical equipment provider’s stock valued at $150,000 after buying an additional 558 shares in the last quarter. Finally, Metropolitan Life Insurance Co NY lifted its holdings in shares of Intersect ENT by 119,788.9% in the second quarter. Metropolitan Life Insurance Co NY now owns 10,790 shares of the medical equipment provider’s stock valued at $184,000 after purchasing an additional 10,781 shares in the last quarter. 92.85% of the stock is currently owned by institutional investors and hedge funds.

NASDAQ XENT opened at $27.23 on Friday. The stock’s 50 day moving average price is $27.14 and its two-hundred day moving average price is $25.71. The company has a debt-to-equity ratio of 6.89, a quick ratio of 1.97 and a current ratio of 2.36. Intersect ENT, Inc. has a 52 week low of $15.92 and a 52 week high of $28.17.

Intersect ENT (NASDAQ:XENT) last announced its quarterly earnings data on Tuesday, November 2nd. The medical equipment provider reported ($0.48) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.06). Intersect ENT had a negative return on equity of 151.36% and a negative net margin of 85.02%. The company had revenue of $24.40 million for the quarter, compared to the consensus estimate of $29.63 million. Analysts anticipate that Intersect ENT, Inc. will post -1.78 earnings per share for the current year.

Intersect ENT Company Profile

Intersect ENT, Inc is a commercial drug delivery company, which engages in the treatment of ear, nose, and throat conditions. Its products include PROPEL and SINUVA. The PROPEL used to maintain the opening and locally deliver steroid after sinus surgery. The SINUVA is used to treat adult patients with ethmoid sinus surgery yet suffer from recurrent sinus obstruction due to polyps.

Featured Story: Short Selling

Institutional Ownership by Quarter for Intersect ENT (NASDAQ:XENT)

Receive News & Ratings for Intersect ENT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT and related companies with MarketBeat.com's FREE daily email newsletter.